Author Guidelines
Instructions for Chinese Journal of Lung Cancer International Authors
Description
Chinese Journal of Lung Cancer(CJLC, ISSN 1009-3419, CN 12-1395/R) is published bimonthly in Chinese and English, hosted by the Chinese Anti-Cancer Association and the Chinese Antituberculosis Association, Tianjin General Hosptial. CJLC was established in 1998 and indexed in EMBASE/SCOPUS, CA,
CAB Abstract, Global Health, CINAHL, CSA, etc.
This journal aims to publish original laboratory and clinical investigations related to lung cancer.. The Journal publishes editorials, perspectives, original research, review articles, short communications, case reports on clinical and basic science aspects of topics represented by the fields of interest of Lung Cancer (prevention, epidemiology and etiology, basic biology, pathology, clinical assessment, surgery, chemotherapy, radiotherapy, etc).
Submission to the journal
Full-length original research articles, review articles and Editorials on clinical and basic aspects of topics represented by the fields of interest of Lung Cancer are welcome. Short communications and Case Reports should be focused on major new developments of general interest to the Lung Cancer readership.
Manuscripts should be submitted online at http://mc03.manuscriptcentral.com/cjlc(Chinese); http://mc03.manuscriptcentral.com/lc(English).
Editorial Office:
Chinese Journal of Lung Cancer
228 Nanjing Rd. Tianjin 300020 China
Tel : 86-(0)22-2721 9052, 86- (0)22-2721 9219
Fax : 86-(0)22-2721 9052
Email : cnlungca@yahoo.com.cn
In a covering letter, please identify the person responsible for editorial correspondence (address, telephone and fax numbers, mobile phone and e-mail address). All authors should have made substantial contributions to all of the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectual content, (3) final approval of the version to be submitted. Also include details of any previous submission.
Acknowledgements All contributors who do not meet the criteria for authorship as defined above should be listed in an acknowledgements section.
Randomised controlled trials Chinese Journal of Lung Cancer recommends that authors adopt the proposal from the International Committee of Medical Journal Editors (ICMJE) which require, as a condition of consideration for publication of clinical trials, registration in a public trials registry. Trials must register at or before the onset of patient enrolment. The clinical trial registration number should be included at the end of the abstract of the article. For this purpose, a clinical trial is defined as any research project that prospectively assigns human subjects to intervention or comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome. Studies designed for other purposes, such as to study pharmacokinetics or major toxicity (e.g. phase I trials) would be exempt. Further information can be found at External link www.icmje.org.
Author Fees
This journal charges the following author fees.
Fast-Track Review: 0.00 (CNY)
With the payment of this fee, the review, editorial decision, and author notification on this manuscript is guaranteed to take place within 4 weeks.
Article Publication: 1000.00 (CNY)
If this paper is accepted for publication, you will be asked to pay an Article Publication Fee to cover publications costs.
If you do not have funds to pay such fees, you will have an opportunity to waive each fee. We do not want fees to prevent the publication of worthy work.
